Th1/Tc1 Immunotherapy Following Stem Cell Transplantation in Multiple Myeloma

NCT01239368 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

34

Enrollment

NIH

Sponsor class

Stopped Terminated due to insufficient accrual.

Conditions

Myeloma, Plasma-Cell
Myeloma-Multiple
Myelomatosis

Interventions

PROCEDURE: Adoptive Immunotherapy
BIOLOGICAL: Rapamycin-Generated Autologous Th1/Tc1 Cells (modified primary human T cells)
BIOLOGICAL: Th1/Tc1 Rapa Cell Therapy

Sponsor

National Cancer Institute (NCI)

Collaborators

[object Object]
[object Object]